Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Commentary|Videos|August 18, 2025
Vaccine Policy Shifts, Public Trust, and Countering Misinformation
Author(s)Amesh Adalja, MD, Sydney Jennings
Fact checked by: Grace Halsey
Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during National Immunization Awareness Month.
Advertisement
Vaccine misinformation and shifting policy guidance continue to challenge physicians as they prepare patients for another respiratory virus season. In this video, infectious disease expert Amesh Adalja, MD, discusses recent changes to COVID-19 and influenza vaccine recommendations, strategies for addressing safety myths, and how primary care physicians can build trust and strengthen vaccine confidence during National Immunization Awareness Month.
Amesh Adalja, MD, is an adjunct assistant professor at the Johns Hopkins Bloomberg School of Public Health and founder of
More From This Interview Series
Explore additional insights from Dr Adalja on vaccine policy and patient communication:
Advertisement
Related to this article
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
4
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
5